Archer Daniels Stock: Analyst Estimates & Ratings

Headquartered in Chicago, Illinois, Archer-Daniels-Midland Company (ADM) plays a major role across the global agricultural and nutrition landscape, connecting local needs with global capabilities to help strengthen food security. The company manages and processes agricultural supply chains while providing a broad portfolio of ingredients and solutions for both human and animal nutrition. Beyond food and nutrition, ADM is also expanding its focus on health and well-being, offering products for consumers seeking healthier lifestyles, while its innovation efforts are opening the door to new bio-based solutions for consumer and industrial applications.

With a market capitalization of roughly $36.91 billion, Archer Daniels has been attracting plenty of attention on Wall Street as its shares continue to build momentum. The stock has climbed an impressive 32.4% over the past year, with that strength carrying into 2026 as well. Shares are already up another 33.2% year to date (YTD). For perspective, the broader S&P 500 Index ($SPX) has gained 22.4% over the past year and 13.3% so far in 2026, putting ADM comfortably ahead of the benchmark on both timeframes.

ADM’s outperformance becomes even more striking when compared with its sector. The State Street Consumer Staples Select Sector SPDR ETF (XLP) has risen just 3.5% over the past year and 9.6% year to date, highlighting just how strongly ADM has outpaced the broader consumer staples space.

ADM’s strong run over the past year and into 2026 hasn’t happened by chance. The company has been working to strengthen its position as a global agricultural and nutrition powerhouse, with a strategy centered on portfolio optimization, tighter cost discipline, and continued innovation. At the same time, strong fundamentals, a constructive biofuels regulatory environment, and solid momentum in its Nutrition and Carbohydrate Solutions segments have added to the stock’s appeal.

That momentum got another boost on August 4, when ADM shares climbed about 2.3% following the release of its fiscal 2026 second-quarter earnings report, one of the company’s strongest quarters in years. The results marked a notable improvement from the year-ago period and gave investors plenty to digest. Revenue rose 7.2% year over year to $22.68 billion, comfortably ahead of Wall Street’s $22.19 billion estimate. But the real standout was the bottom line. Adjusted EPS nearly doubled, soaring 97.8% year over year to $1.84, handily beating analysts’ estimate of $1.42.

Looking ahead, Wall Street expects ADM’s earnings momentum to continue. For the current fiscal year ending in December, analysts project diluted EPS of $5.46, representing a notable 59.2% increase year over year. ADM also has a solid track record when it comes to delivering beyond expectations. The company has beaten consensus earnings estimates in each of the past four quarters.

ADM may be enjoying strong momentum, but Wall Street isn’t fully convinced just yet. The stock currently carries a consensus “Hold” rating, reflecting a more measured view despite the company’s recent outperformance and strong earnings growth. Among the 10 analysts covering ADM, two rate the stock a “Strong Buy,” six recommend “Hold,” one gives it a “Moderate Sell,” and one has a “Strong Sell” rating. 

Still, there’s a subtle shift worth noting. Analyst sentiment has become slightly more bullish over the past month. One month ago, the stock had only one “Strong Buy” rating, while two analysts had rated it “Strong Sell.” The shift suggests that ADM’s improving fundamentals and recent earnings strength may be gradually winning over some skeptics.

JPMorgan raised its price target to $77 from $74 in early August 2026, following earlier target increases by the firm this year as industry conditions improved and biofuels policy developments provided a more supportive backdrop. The broader analyst outlook also points to further upside. The average price target of $83.22 suggests the stock could gain roughly 8.7% from current levels, while the Street-high target of $95 implies potential upside of as much as 24%.